Hepatitis b drug showdown: which is safer for kidneys?

NCT ID NCT03933384

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two antiviral drugs, tenofovir alafenamide (TAF) and entecavir, in 140 adults with chronic hepatitis B. The goal is to see which one controls the virus better and causes fewer kidney problems. Participants take one pill daily for about a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tenofovir alafenamide (TAF) and entecavir

What this could lead to

If successful, this could show that TAF is as effective as entecavir at suppressing hepatitis B virus, with better kidney safety.

What could go wrong

This is a relatively small, open-label trial (not blinded), so results may be less reliable. Both drugs are already approved; the study compares them rather than testing a new cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection viral hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, Taichung, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••